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Antibody-drug conjugatesTrastuzumab emtansine (T-DM1) is the ﬁrst antibody-drug conjugate (ADC) approved for patients with human
epidermal growth factor receptor 2 (HER2)-positivemetastatic breast cancer. The therapeutic premise of ADCs is
based on the hypothesis that targeted delivery of potent cytotoxic drugs to tumorswill provide better tolerability
and efﬁcacy compared with non-targeted delivery, where poor tolerability can limit efﬁcacious doses. Here, we
present results frompreclinical studies characterizing the toxicity proﬁle of T-DM1, including limited assessment
of unconjugated DM1. T-DM1 binds primate ErbB2 and human HER2 but not the rodent homolog c-neu. There-
fore, antigen-dependent and non-antigen-dependent toxicitywas evaluated inmonkeys and rats, respectively, in
both single- and repeat-dose studies; toxicity of DM1 was assessed in rats only. T-DM1 was well tolerated at
doses up to 40 mg/kg (~4400 μg DM1/m2) and 30 mg/kg (~6000 μg DM1/m2) in rats andmonkeys, respective-
ly. In contrast, DM1 was only tolerated up to 0.2 mg/kg (1600 μg DM1/m2). This suggests that at least two-fold
higher doses of the cytotoxic agent are tolerated in T-DM1, supporting the premise of ADCs to improve the ther-
apeutic index. In addition, T-DM1 and DM1 safety proﬁles were similar and consistent with the mechanism of
action of DM1 (i.e., microtubule disruption). Findings included hepatic, bone marrow/hematologic (primarily
platelet), lymphoid organ, and neuronal toxicities, and increased numbers of cells of epithelial and phagocytic or-
igin inmetaphase arrest. These adverse effects did notworsenwith chronic dosing inmonkeys and are consistent
with those reported in T-DM1-treated patients to date.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
The human epidermal growth factor receptor 2 (HER2, also known
as ErbB2) is a transmembrane receptor tyrosine kinase that is part of a
complex signal transduction network involved in cell differentiation,
proliferation, and survival (Yarden and Sliwkowski, 2001). HER2 is
expressed in normal epithelial tissues at relatively low levels in healthy
adults (Press et al., 1990), but it is overexpressed in approximately 20%
of tumors from patients with breast cancer (Dawood et al., 2010; Ross
et al., 2009). HER2-positive breast tumors are associated with aggres-
sive growth and poor clinical outcomes (Slamon et al., 1987, 1989).
The association between HER2 overexpression and tumor pathogenesis
in breast cancer, together with the accessibility of the extracellularAWay, South San Francisco, CA
.
.Open access under CC BY-NC-ND licedomain of the receptor, has made HER2 a suitable target for antibody
therapy.
Trastuzumab (Herceptin®, Genentech, Inc., South San Francisco, CA)
is a humanized monoclonal antibody directed against subdomain IV of
the extracellular region of HER2 and is indicated for the treatment of
HER2-overexpressing breast cancer and HER2-overexpressing meta-
static gastric or gastroesophageal junction adenocarcinoma (Herceptin
package insert, 2010; Herceptin Summary of Product Characteristics,
2010). The mechanisms of action are thought to include one or more
of the following: interference with signal transduction pathways,
impairment of extracellular domain (ECD) cleavage, inhibition of DNA
repair, decreased angiogenesis, induction of cell cycle arrest, and
activation of antibody-dependent cellular cytotoxicity (Hudis, 2007;
Sliwkowski et al., 1999; Spector and Blackwell, 2009). Although
trastuzumab provides substantial beneﬁts for many patients with
HER2-positive breast cancer, a proportion have tumors that either do
not respond to trastuzumab or relapse following initial response to
treatment (Nahta et al., 2006; Slamon et al., 2001). Following relapse,
HER2 overexpression is still present (Spector et al., 2005), suggesting
that these tumors could still be responsive to treatment with HER2-
targeted agents. Indeed, two phase III clinical trials have shown in pa-
tients with tumors that progressed on trastuzumab-containing therapynse.
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signiﬁcantly improved clinical outcomes (Blackwell et al., 2010; von
Minckwitz et al., 2009, 2011).
An alternative to targeted antibody therapy and/or systemic chemo-
therapy is theuse of antibody-drug conjugates (ADCs). ADCs are created
by chemically linking a cytotoxic agent to a monoclonal antibody that
targets a tumor-enriched or tumor-speciﬁc protein. Tumor-speciﬁc
delivery of potent cytotoxic agents has the potential to ameliorate the
systemic toxicity associated with many chemotherapies (Alley et al.,
2010; Lambert, 2005; Wu and Senter, 2005).
Trastuzumab emtansine (T-DM1, Kadcyla™, Genentech, Inc., South
San Francisco, CA) is an ADC composed of trastuzumab, a nonreducible
thioether linker (4-[N-maleimidomethyl]-cyclohexane-1-carbonyl
[MCC]) (Lewis Phillips et al., 2008), and the cytotoxic agent DM1
(N2′-deacetyl-N2′-(3-mercapto-1-oxopropyl) maytansine) (Blättler
and Chari, 2001; Cassady et al., 2004; Goldmacher et al., 2002)
(Fig. 1). DM1 is derived from the highly potent antitumor agent
maytansine and inhibits microtubule polymerization (Cabanillas
et al., 1978; Chabner et al., 1978; Eagan et al., 1978; Issell and
Crooke, 1978; Remillard et al., 1975). T-DM1 comprises trastuzumab
with zero to eight DM1molecules linked viaMCC, primarily to lysine
residues, and has an average drug-to-antibody ratio (DAR) of ap-
proximately 3.5 (Krop et al., 2010). After T-DM1 binds to HER2 on
the cell surface, the T-DM1/HER2 complex is internalized via endo-
cytosis and degraded in lysosomes, ultimately leading to the intra-
cellular release of lysine-MCC-DM1 (lys-MCC-DM1) (Chari, 2008;
Erickson et al., 2006, 2010). In the phase III EMILIA study, patients
with HER2-positive, metastatic breast cancer previously treated with
trastuzumab and a taxane received treatment with either T-DM1 or
lapatinib plus capecitabine. Patientswho received T-DM1had signiﬁcant-
ly improved clinical outcomes compared with patients treated with
lapatinib plus capecitabine (Verma et al., 2012). Median progression-
free survival was 9.6 months versus 6.4 months in the T-DM1 and con-
trol arms, respectively (hazard ratio = 0.65; 95% conﬁdence interval
[CI]: 0.55 − 0.77; p b 0.001). Median overall survival also improved
and was 30.9 months versus 25.1 months in the respective treatment
arms (hazard ratio = 0.68; 95% CI: 0.55 − 0.85: p b 0.001) (Verma
et al., 2012).
The preclinical and clinical toxicities of trastuzumab andmaytansine
(the parent compound of DM1) have been extensively characterized. In
single- and repeat-dose toxicity studies of trastuzumab in cynomolgus
monkeys, no adverse effects were observed, although trastuzumab-
related cardiotoxicity and embryotoxicity had been previously identi-
ﬁed in the clinical setting at low frequencies (Herceptin Summary
of Product Characteristics, 2010; Herceptin® package insert, 2010;
Klein and Dybdal, 2003). DM1 and maytansine are closely related
chemical entities; DM1 differs from maytansine only in the replace-
ment of a methyl group with a thioethyl group to enable conjugation.
Maytansine-associated preclinical and clinical toxicities included ad-
verse effects on the liver, bone marrow, lymphoid organs, gastroin-
testinal tract, and central/peripheral nervous system (Issell and
Crooke, 1978). The established clinical dose of 3.6 mg/kg T-DM1 de-
livers molar equivalent doses of DM1 that are only slightly higher
(~2.3 mg/m2) than themaytansineMTDbutwith a signiﬁcant improve-
ment in efﬁcacy and safety.
We sought to characterize the safety of T-DM1 and to understand
the drivers of toxicity to support its clinical development. The
trastuzumab component of T-DM1 binds to nonhuman primate ErbB2
and human HER2 but does not cross-react with the corresponding
rodent receptor (c-neu) (data on ﬁle at Genentech, Inc., South San
Francisco CA), limiting the assessment of antigen-dependent effects to
non-human primates. As rodents have been shown to be sensitive to
the DM1 parent compound maytansine (Issell and Crooke, 1978), rats
were used to evaluate the antigen-independent effects of T-DM1 and
compare them with toxicities associated with DM1. Cross-species
comparisons were possible because of the selection of T-DM1 dosesthat resulted in equivalent DM1 doses based on body surface area
(μg DM1/m2).
Methods
General animal information. All procedures in animals described
below were performed in compliance with the Animal Welfare Act,
the Guide for the Care and Use of Laboratory Animals, and the Ofﬁce
of Laboratory Animal Welfare. Protocols were reviewed by the Institu-
tional Animal Care and Use Committees of the relevant facility; either
Genentech, Inc. (South San Francisco, CA), or Covance, Inc. (Madison,
WI). Sprague–Dawley rats were obtained from Charles River Laborato-
ries (Portage, MI, or Hollister, CA). Cynomolgus monkeys (Macaca
fascicularis) were obtained from Three Springs Scientiﬁc, Inc. (Perkasie,
PA), or Covance Research Products, Inc. (Alice, TX). All animals were
individually housed in stainless-steel cages and were provided with
food supplements (that did not require analysis) and various cage-
enrichment devices. Monkeys were commingled to provide psycholog-
ical enrichment. Animalswere assigned to dose groups using a stratiﬁed
randomization scheme based on individual body weight. For scheduled
or unscheduled necropsies, rats were euthanized with isoﬂurane
followed by an overdose of a ketamine/xylazine cocktail or sodium
pentobarbital; monkeys were terminally sedated with sodium pento-
barbital and euthanized by exsanguination.
Intravenous dose formulations. T-DM1 was formulated in a vehicle
composed of 10 mMsuccinate, 100 mg/mL trehalose, and 0.1% polysor-
bate 20, pH 5.0. DM1 was formulated in the T-DM1 vehicle plus 0.5%
dimethyl adipimidate and 1 mM ethylenediaminetetraacetic acid. The
average DAR was 3.4 for all studies, with the exception of the repeat-
dose (every 3 weeks [q3w] × eight doses) monkey study where the
DAR was 3.8.
Parameters for the evaluation of toxicity. Toxicity indices consisted of
daily clinical observations, body weight, food consumption, clinical
pathology, organ weights, and histopathology. Additionally, physical
examinations (includingneurologic assessment) and ophthalmic exam-
inationswere conducted in the repeat-dosemonkey studies. Necropsies
included examination of the carcass; external body oriﬁces; abdominal,
thoracic, and cranial cavities; and organs. Tissues collected at necropsy
were preserved in 10% neutral-buffered formalin ormodiﬁed Davidson's
ﬁxative andwere processed for routine histologic examination. Select or-
gans were weighed prior to ﬁxation.
Rat studies of T-DM1 and DM1. The toxicity of T-DM1 was evaluated
in single- and repeat-dose studies in rats (Table 1A). In the ﬁrst single-
dose study, rats were dosed intravenously (IV) on day 1 with vehicle
alone or 6, 20, or 60 mg/kg T-DM1 (n = 10 animals/sex/group). Six
additional animals (n = 3 animals/sex/group) were assigned to each
T-DM1-treated group for toxicokinetic (TK) analyses (described in the
Toxicokinetic analyses section). Body weights and food consumption
were recorded on days 1, 3, 5, 8, 15, and 22. A necropsy was conducted
2 days postdose (day 3) (n = 5 animals/sex/group), and a second
necropsy was conducted following a 3-week recovery period (day 22).
Additionally, an unscheduled necropsy was performed for animals de-
termined to be moribund on day 5 or 6. In the second single-dose
study, rats were injected IV on day 1 with vehicle alone or 46 mg/kg
T-DM1 (n = 5 females/group). Body weights were recorded daily,
and a necropsy was conducted 11 days postdose (day 12). In the
repeat-dose study, rats (n = 6 females/group) were administered
T-DM1 weekly for a total of three IV doses that ranged from 4 to 5,
9 to 13, and 18 to 25 mg/kg T-DM1. Body weights were recorded
daily, and a necropsy was conducted 3 weeks after the third dose
(day 36). An unscheduled necropsy was also performed (including
blood collection for clinical pathology and TK) for animals in the
high-dose group determined to be moribund on day 24. The toxicity
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Fig. 1. Trastuzumab emtansine is an antibody-drug conjugate composed of trastuzumab (a humanized anti-HER2 IgG1), MCC (a nonreducible thioether linker), and DM1 (amicrotubule-
inhibitorymaytansinoid). The bracketed structure is DM1 plusMCC,which is linked to antibody lysine residues on trastuzumab. The n is, on average, 3.5 per trastuzumabmolecule. HER2:
human epidermal growth factor 2; IgG1, immunoglobulin G1; MCC: 4-[N-maleimidomethyl]-cyclohexane-1-carbonyl.
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ﬁnding study and a deﬁnitive study. The dose range-ﬁnding study
was conducted at IV doses of 0 mg/kg (vehicle, n = 2), 0.1, 0.2, 0.4,
0.6, 0.8, or 1.0 mg/kg (n = 6 animals/group), followed by a deﬁni-
tive study at doses of 0 mg/kg (vehicle), 0.07, 0.1, or 0.2 mg/kg
(n = 10 animals/sex/group). In the dose range-ﬁnding study, body
weights were measured on day 1 prior to DM1 administration and
daily thereafter. An unscheduled blood collection and necropsy
were also performed for animals determined to be moribund on
day 3 or 4. The study design for the deﬁnitive study of DM1 in rats
was identical to the single-dose study of T-DM1 in rats described
previously, with blood collections and necropsy on days 3 and 22.Table 1A
Summary of study designs and sampling schedules for rat studies of T-DM1 and DM1.
N/group Regimen/recovery Day 1 mean body
weight range
Dose T-DM1 or DM1
(mg/kg)b
T-DM1 10 (F)a
10 (M)a
Single dose/3 weeks 199–202 g (F)
305–309 g (M)
6
20
60d
5 (F) Single dose/11 days 122 g (F) 46
6 (F) Weekly × 3 doses/3 weeks 110–117 g (F) 5
11
22
DM1 6 (F) Single dose/11 days 119–121 g (F) 0.1
0.2
0.4d
0.6d
0.8d
1.0d
10 (F)a
10 (M)a
Single dose/3 weeks 212–214 g (F)
317–322 g (M)
0.07
0.1
0.2
a Toxicokinetics sampling from satellite animals (n = 3/sex/group).
b mg/kg T-DM1 = mg antibody (trastuzumab) per kg body weight; mg/kg DM1 = mg DM
c BSA (body surface area)-based equivalent dose of DM1 (μg/m2) calculated as follows: for T-
of DM1 to trastuzumab in T-DM1) × 1000/BSA) (m2)]. For DM1, [dose level (mg/kg DM1) ×
mean body weight, [g])0.66 × 9.1 (Meeh's constant) / 10,000]. Fraction of DM1 to trastuzum
trastuzumab (MW 145, 167), and the measured drug/antibody ratio (DAR 3.4), and calculated
d Animals found dead or euthanized in a moribund condition.Monkey studies of T-DM1. The toxicity of T-DM1 was evaluated in
single- and repeat-dose studies (q3w × four doses and q3w × eight
doses) in cynomolgus monkeys (Table 1B). Owing to the anticipated
clinical dosing schedule (q3w), we wanted to understand the toxicities
following a single exposure before setting doses for a multidose study.
In the single-dose study, monkeys were administered IV doses of
T-DM1 on day 1 at 0 (vehicle), 3, 10, and 30 mg/kg (n = 6 animals/
sex/group). Bodyweightswere recorded prior to T-DM1 administration
andweekly thereafter. Food consumptionwas assessed qualitatively on
a daily basis. Necropsies were conducted 2 days postdose (study day 3)
and following a 3-week recovery period (study day 22) on the basis
of the intended clinical dosing regimen of q3w administration. TKBSA-based equivalent
dose of DM1
(μg DM1/m2)c
Hematology/serum
chemistry sampling
schedule
(study day)
TK sampling schedule
(days)
700 (F), 800 (M)
2300 (F), 2600 (M)
6800 (F) d, 7800 (M)d
3, 22 1 (10, 24 h postdose), 4, 8, 15, 22
4400 5, 12 Day 12
500
1000
2100
5, 12, 19, and 24 or 36 Day 24 or 36
600
1100
2200d
3400d
4500d
5600d
3, 5, 12 No data available
500 (F), 500 (M)
700 (F), 800 (M)
1400 (F), 1600 (M)
3, 8, 22 1 (5 min, 1, 6, 24 h postdose), 3, 22
1 per kg body weight.
DM1, [dose level (mg/kg T-DM1) × day 1 groupmean bodyweight (kg) × 0.017 (fraction
day 1 group mean body weight (kg) × 1000 / BSA) (m2)]. BSA calculation [(day 1 group
ab in T-DM1 determined using the molecular weights (MW) of DM1 (MW 738) and
as follows: MW DM1 × DAR) / MW trastuzumab.
Table 1B
Summary of study designs and sampling schedules for monkey studies of T-DM1.
N/group Regimen/recovery Day 1 mean body
weight range
Dose T-DM1
or DM1
(mg/kg)a
BSA-based equivalent
dose of DM1
(μg DM1/m2)b
Hematology/serum chemistry
sampling schedule
(study day)
TK/ATA sampling schedule
(days)
T-DM1 6 (F)
6 (M)
Single dose/3 weeks 2.8–2.9 kg (F)
3.4–3.6 kg (M)
3
10
30
600
2000
6000
3, 8, 15, 22 1 (5 min postdose), 3, 4, 8, 15, 22c
7 (F)
7 (M)
Repeat dose
(q3w × 4 doses)/3
or 6 weeks
2.8 kg (F)
3.1–3.2 kg (M)
3
10
30
600
2000
6000
3, 22c, 24, 43c, 45, 64c, 66,
85, 94, 106
1 (5 min, 6, 10, 24 h postdose),
3, 6, 22c (predose), 43c (predose),
64c (predose), 65, 67, 69, 71, 78, 85c,
94, 106c
6 (F)
6 (M)
Repeat dose
(q3w × 8 doses)/3
or 6 weeks
2.5–2.6 kg (F)
3.0–3.1 kg (M)
1
3
10
200
600
2000
4, 8, 22c, 43c, 64c, 85c,
106c, 127c, 148c, 151,
155, 169, & 190
1 (5 min, 4, 8, 24 h postdose),
4, 7, 15, 43d (predose, 5 min postdose),
64d (predose, 5 min, 4, 8, 24 h postdose),
67, 70, 78, 85d (predose, 5 min postdose),
127d (predose, 5 min postdose),
148d (predose, 5 min, 4, 8, 24 h postdose),
151, 154, 162, 169d, 176, 183, 190d
a mg/kg T-DM1 = mg antibody (trastuzumab) per kg body weight.
b BSA (body surface area)-based equivalent dose of DM1 (μg/m2) calculated as follows: [dose level (mg/kg T-DM1) × 12 × 0.017 or 0.019 (fraction of DM1 to trastuzumab in T-DM1 for
single-dose and 4-dose study, or 8-dose study, respectively) × 1000)]. Fraction of DM1 to trastuzumab in T-DM1 determined using the molecular weights (MW) of DM1 (MW 738) and
trastuzumab (MW 145, 167), and the measured drug/antibody ratio (DAR 3.4 for single-dose and 4-dose study, or 3.8 for the 8-dose study), and calculated as follows: MW
DM1 × DAR) / MW trastuzumab. The conversion factor of 12 for cynomolgus monkeys was taken from the Handbook of Toxicology, 2nd Edition, CRC Press, 1995. Equivalents of DM1
are based on a 3 kg animal, and will vary for the body weight of each animal.
c Predose.
d Blood samples collected predose for ATA (anti-therapeutic antibody) analysis.
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performed (assays described in the Toxicokinetic analyses section and
Assay to detect antitherapeutic antibody response to T-DM1 section).
In the ﬁrst repeat-dose study (q3w × four doses), monkeys were
administered IV doses of T-DM1 on days 1, 22, 43, and 64 at 0 (vehicle),
3, 10, and 30 mg/kg (n = 7 animals/sex/group). Body weight and food
consumption were recorded as described previously for the single-dose
study. Ophthalmologic examinations were performed prior to treat-
ment and during weeks 3 and 9 using a handheld slit lamp and an indi-
rect ophthalmoscope. Neurologic and physical examinations were
performed prior to treatment and during weeks 3 and 9. Electrocardio-
gram (ECG) rate and heart rate (HR) were recorded prior to treatment
and during weeks 2, 8, 12, and 15. For ECG examination, routine
measurements of HR, and PR, QRS, QT, corrected QT interval (QTc;
calculated), and RR intervals were conducted. Qualitative assessments
of ECG traces for rhythm and abnormalities were also performed. Clini-
cal pathology TK (described in the Toxicokinetic analyses section [Dere
et al., 2013]) and ATA samples (described in the Assay to detect anti-
therapeutic antibody response to T-DM1 section [Carrasco-Triguero
et al., 2013]) were collected as summarized in Table 1B. Necropsies
were conducted 2 days after the fourth dose on day 66 (n = 3
animals/sex/group), 3 weeks after the fourth dose on day 85 (n = 2
animals/sex/group), and 6 weeks after the fourth dose on day 106
(n = 2 animals/sex/group). In the second repeat-dose study (q3w ×
eight doses), monkeys were administered IV doses of T-DM1 on days
1, 22, 43, 64, 85, 106, 127, and 148 at 0 (vehicle), 1, 3, and 10 mg/kg
(n = 6 animals/sex/group) to evaluate the chronic effects of T-DM1.
Body weight and food consumption were recorded as described previ-
ously for the single-dose study. Ophthalmologic, physical, and neuro-
logic examinations; body temperature; respiration rates; and pulse
oximetry measurements were performed prior to T-DM1 administra-
tion, once after the ﬁrst dose, after the eighth dose, and again during
the last week of the recovery period. ECG and HR were recorded twice
prior to T-DM1 administration: once after the ﬁrst dose, fourth dose,
eighth dose, and during the last week of the recovery period. ECG mea-
surements and qualitative assessments were performed as described
for the repeat-dose (q3w × four doses) toxicity study inmonkeys. Clin-
ical pathology TK and ATA samples were collected as summarized in
Table 1B. Necropsies were conducted 7 days after the ﬁnal dose (n =
3 animals/sex/group) on day 155, and after a 6-week recovery period
(n = 3 animals/sex/group) on day 190.Pharmacology study of cardiovascular safety of single-dose T-DM1 in
cynomolgus monkeys. Female cynomolgus monkeys were admin-
istered a single IV bolus dose of vehicle alone or 3, 10, or 30 mg/kg
T-DM1 (n = 4 animals/group). At least 3 weeks prior to initiation
of treatment, animalswere surgically implantedwith a telemetry trans-
mitter (Data Sciences, International [DSI Dataquest™ Open Art™] and
Gould/PoNeMah® [P3P (PoNeMah Physiology Platform)] acquisition
system). A large animal ECG and a pressure transmitter (Model #D70
PCTP)were implanted into the abdomen. The ECG leads of the transmit-
terwere arranged in an approximate lead II conﬁguration. One pressure
line, which was used to assess blood pressure (BP), was placed in the
abdominal aorta. The second pressure line, whichwas used to assess in-
trathoracic pressure, was placed on the thoracic side of the diaphragm.
ECG and BP measurements were recorded as follows: twice in the 2-
week period prior to T-DM1 administration (at least 7 days apart);
prior to dosing on day 1 for at least 60 min; continuously through 8 h
postdose; for a 10-minute period each hour through 24 h postdose;
and on days 3, 4, 5, 8, 15, and 22 for at least 10 min at approximately
the same time of day as dosing. Quantitative evaluation of ECG mea-
surements included RR interval (for use in rate correction), QT
interval, and QTc, using Fridericia's method. BPmeasurements included
HR, systolic (SBP), diastolic (DBP), andmean arterial pressure and pulse
pressure (systolic–diastolic). Intrathoracic pressure measurements in-
cluded respiratory rate and a qualitative assessment of respiratory
depth.
In vitro human ether-à-go-go-related gene assay (DM1). The
concentration–response relationship of the effect of DM1 on the potas-
sium channel current of the human ether-à-go-go-related gene (hERG)
was evaluated at ChanTest® (ChanTest Corporation, Cleveland, OH)
(ChanTest®hERG IC50 Concentration Response Assays, 2013) using stan-
dard hERG IC50 (half-maximal inhibition determined by electro-
physiology) methodologies. DM1 concentrations of 2.6, 8.8, and
29.5 μM were evaluated. The positive control was 60 nM of terfenadine.
Tissue cross-reactivity. The immunohistochemical cross-reactivity and
distribution of reactivity of T-DM1 were assessed on cryosections of a
complete panel of human and cynomolgus monkey tissues. T-DM1 bind-
ing was evaluated at concentrations of 1.0 μg/mL and 10.0 μg/mL and de-
tected immunohistochemicallywith an anti-DM1/biotinylated antimouse
immunoglobulin G (IgG) secondary/tertiary antibody complex.
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the single-dose study of T-DM1 in rats and cynomolgus monkeys, in the
deﬁnitive single-dose study of DM1 in rats, and in the repeat-dose and
chronic toxicity studies of T-DM1 in cynomolgus monkeys. Parameters,
including but not limited to area under the concentration–time curve
(AUC), maximum concentration, terminal half-life (t½), clearance (CL),
and volume of distribution, were estimated, as applicable. In rats, inten-
sive blood samplingwas performed using satellite animals thatwere ad-
ministered the same doses as the animals dosed for toxicity evaluations.
In monkeys, intensive sampling occurred during the ﬁrst and last dose
cycles (cycles 1, 4, or 8) with a collection of peak and trough samples
for the interim dose cycles. Validated assays (developed by Genentech,
Inc.) were used tomeasure speciﬁc analytes in the samples and included
an enzyme-linked immunosorbent assay (ELISA) for T-DM1 conjugate,
an ELISA for total trastuzumab, and a liquid chromatography with tan-
dem mass spectrometry (LC–MS/MS) assay for DM1 (see the following
sections).
T-DM1 ELISA. The T-DM1 ELISA was designed to measure all T-DM1
DARs except DAR 0 in serum. Anti-DM1 monoclonal antibody was
used as the capture reagent, and biotinylated recombinant HER2 ECD
and horseradish peroxidase-conjugated streptavidin was used for
detection. The minimum quantiﬁable concentrations in rat and cyno-
molgus monkey serum were 30 ng/mL and 40 ng/mL, respectively.
Total trastuzumab ELISA. The total trastuzumab ELISA was designed to
measure all T-DM1 DARs, including conjugated T-DM1, as well as
partially unconjugated and fully unconjugated T-DM1 in serum. Recom-
binant HER2 ECD was used as the capture reagent and peroxidase-
conjugated F(ab′)2 goat antihuman IgG Fc was used for detection. The
minimum quantiﬁable concentration in both rat and cynomolgus mon-
key serum was 40 ng/mL.
For both ELISAs, serum samples were quantiﬁed against an assay
standard curve prepared from T-DM1 with an average DAR of approxi-
mately 3.5 (Dere et al., 2013).
Unconjugated DM1. The liquid chromatography with LC–MS/MS assays
were designed to measure DM1 and any disulﬁde-bound forms of re-
leased DM1 (e.g., dimers, glutathione, cysteine, and albumin adducts)
in rat and cynomolgus monkey lithium heparin plasma; the assay did
not measure DM1 conjugated to trastuzumab via MCC-DM1. Because
DM1 contains a free sulfhydryl, any DM1 released from T-DM1 is
expected to rapidly dimerize or react with other thiol-containingmole-
cules in plasma. Therefore, to avoid underquantiﬁcation of released
DM1, plasma samples were treated with a reducing agent (tris [2-
carboxyethyl]phosphine) to release disulﬁde-bound DM1. The free
thiol was then blocked with N-ethylmaleimide (NEM) to prevent any
further reactions. The LC–MS/MS assays quantiﬁed DM1-NEM. DM1
was extracted from plasma samples by protein precipitation using
acetonitrile and online solid-phase extraction for all studies noted
except the chronic toxicity study. For the chronic monkey toxicity
study, DM1 was extracted from plasma by protein precipitation using
acetonitrile. DM1, derivatizedwithNEM,was analyzed using electrospray
LC–MS/MS. The LC–MS/MS assays in rat and cynomolgusmonkey plasma
had a lower limit of quantiﬁcation (LLOQ) of 1.00 nM (0.737 ng/mL). For
the chronic toxicity study, LLOQ was 0.50 nM (0.37 ng/mL).
Assay to detect antitherapeutic antibody response to T-DM1. A validat-
ed bridging antibody electrochemiluminescence assay (Bioveris®, San
Diego, CA) was used to detect ATAs to T-DM1 in cynomolgus monkey
serum samples. The assay was designed to detect all ATA responses
directed against T-DM1 by using biotinylated and ruthenium-labeled
T-DM1 to form bridging complexes with ATAs in the sample. Data
from a panel of serum samples from 72 T-DM1-naive cynomolgus
monkeys were used to establish the screening threshold or cut point
for the assay. To minimize the potential for false-negative results, thescreening cut point was set to give an untreated positive rate of approx-
imately 8%. The relative sensitivity of the assay using anti-T-DM1
afﬁnity-puriﬁed antibodies from cynomolgus monkeys was 65 ng/mL.
The tolerance of the assay to interference by T-DM1 was demonstrated
by the detection of 382 ng/mL antibodies in the presence of 50 μg/mL of
T-DM1.
Statistical analyses. For the single- and repeat-dose DM1 and T-DM1
toxicity studies, continuous clinical pathology values, organ weights,
food consumption values, body weights, and ECG/BP/HR data were
analyzed by factorial analysis of variance/covariance with repeated
measures (when appropriate). The factors used were main effect and
sex; when treatment interactions were signiﬁcant, the sexes were
analyzed separately. Group comparisons were evaluated at the 5.0%
two-tailed probability level. TK parameter estimates were summarized
asmean ± standard deviation (SD). For the cardiovascular safety phar-
macology study, descriptive statistics included means and SD at each
time interval. For statistical analysis, the predosemeanswere combined
into an overall predose value. Repeated measure analyses of variance
were performed for ECG, HR, SBP, DBP, mean BP, pulse pressure, and re-
spiratory rate, with subsequent Bonferroni-adjusted t-test for pairwise
comparisons between treatment and control. Statistical evaluation
was at the 5.0% two-tailed probability level.
Results
Effect of T-DM1 and DM1 in rats
A single IV dose of T-DM1 was well tolerated in rats at doses up
to 46 mg/kg (~4400 μg DM1/m2), but at 60 mg/kg T-DM1 (~6800–
7800 μg DM1/m2 — DM1 dose determined based on female and male
day 1 groupmean bodyweights) decreased bodyweight (Fig. 2A),mor-
bidity (decreased food consumption, abnormal clinical signs; data not
shown), and/or mortality occurred 4 or 5 days postdose (Fig. 2A;
Table 2). In contrast, a single IV dose of DM1 was only tolerated up to
0.2 mg/kg (~1400–1600 μg DM1/m2); doses ≥0.4 mg/kg (~2200 μg
DM1/m2) were associated with mortality, 2 or 3 days postdose, and
body weight decreases (Fig. 2A; Table 2), suggesting that the acute
tolerability of DM1 is improved at least two-fold when conjugated
to trastuzumab and administered as T-DM1. The repeat dose study of
T-DM1 in rats showed that weekly doses (weekly for three doses
total) ranging from approximately 5 mg/kg to 11 mg/kg (~500 to
1000 μg DM1/m2, respectively) were well tolerated (data not shown),
while animals showed signs of morbidity/mortality approximately
1 week after the third dose at 22 mg/kg (~2100 μg DM1/m2, respec-
tively). The cumulative total dose and the timing of adverse effects in
this repeat-dose study were in line with the doses tolerated after a
single dose of T-DM1.
The primary toxicities in rats were comparable between T-DM1
and DM1 and included dose-dependent effects on liver, bone marrow/
hematologic systems (mainly platelets), and lymphoid organs. Hemato-
logic and serum chemistry ﬁndingswere primarily associatedwith bone
marrow suppression and hepatotoxicity (Table 3). Hematologic changes
included decreased platelet (Fig. 2B), reticulocyte, and lymphocyte
counts, as well as increased absolute neutrophil counts, which correlat-
ed with microscopic observations of mild bone marrow hypocellularity
and minimal to moderate lymphoid depletion or necrosis in the lymph
nodes, thymus, and spleen (Tables 4 and 5), accompanied by increased
spleen weights in some animals (data not shown). Changes in serum
chemistry were reﬂective of adverse effects on the liver, including in-
creases in serum alanine aminotransferase (ALT) (Fig. A.1), aspartate
aminotransferase (AST) (Fig. 2C), alkaline phosphatase (ALP), gamma-
glutamyl transpeptidase, and total bilirubin. Increased liver weights
(data not shown) and histopathologic ﬁndings were associated with
these elevations in liver enzymes and consisted ofminimal to severe he-
patocellular degeneration and necrosis (most severe at high doses)with
70
Dose (µg DM1/m 2)
T-DM1 Free DM1
T-DM1 6 mg/kg (700 – 800 µg DM1/m2)
T-DM1 20 mg/kg (2300 – 2600 µg DM1/m2)
T-DM1 46 mg/kg (4400 µg DM1/m 2)
T-DM1 60 mg/kg (6800 – 7800 µg DM1/m2)†
DM1 0.07 mg/kg (500 µg DM1/m 2)
DM1 0.1 mg/kg (700 – 800 µg DM1/m2)
T-DM1 0.2 mg/kg (1400 – 1600 µg DM1/m2)
T-DM1 0.4 mg/kg (2200 µg DM1/m 2)†
T-DM1 0.6 mg/kg (3400 µg DM1/m 2)†
T-DM1 0.8 mg/kg (4500 µg DM1/m 2)†
T-DM1 1.0 mg/kg (5600 µg DM1/m 2)†
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Fig. 2. BW by dose over time (A), day 3 platelet levels (B), and day 3 AST levels (C) from the single-dose intravenous toxicity studies of T-DM1 and DM1 in rats (data for DM1 combined
from two studies). Based on the differences in timing of peak bodyweight decreases andmortality with administration of T-DM1 versus DM1, it is possible that the peak effects on clinical
pathology parameters (and histology)may have occurred slightly later (2- to 3-day delay) in T-DM1-treated rats. Importantly, the toxicity proﬁle is very similar between T-DM1 and DM1
despite differences in tolerability. Groupmean bodyweight data and individual platelet and AST data are expressed as a percent of control. A single T-DM1, DM1, or vehicle dosewas given
on day 1. T-DM1 and DM1 doses are presented as dose equivalents of DM1 per body surface area, μg DM1/m2. AST, aspartate aminotransferase; BW, body weight; T-DM1, trastuzumab
emtansine. † indicates group euthanized in moribund condition/animals found dead ( DM1 0.4 mg/kg (2200 μg DM1/m2), DM1 0.6 mg/kg (3400 μg DM1/m2), DM1 0.8 mg/kg
(4500 μg DM1/m2), DM1 1.0 mg/kg (5600 μg DM1/m2), and T-DM1 60 mg/kg (6800–7800 μg DM1/m2) groups).
303K.A. Poon et al. / Toxicology and Applied Pharmacology 273 (2013) 298–313hypertrophy andvacuolation of Kupffer cells, prominent extramedullary
hematopoiesis, and increasedmitotic ﬁgures (cells arrested in meta-
phase) for hepatocytes, biliary epithelium, and Kupffer cells (see
Tables 4 and 5).Renal tubular epithelium was also affected in rats given either
T-DM1 or DM1 with minimal to slight degeneration, necrosis,
and increased mitotic arrest (see Tables 4 and 5). However,
these ﬁndings were not accompanied by other indicators of renal injury
Table 2
Summary of mortality in rats administered a single-dose of T-DM1 or DM1.
BSA-based equivalent dose of DM1, μg DM1/m2
(mg/kg T-DM1 or DM1)
T-DM1 DM1
– 500 (0.07)
– 600 (0.1)
700 (6) 700 (0.1)
800 (6) 800 (0.1)
– 1100 (0.2)
– 1400 (0.2)
– 1600 (0.2)
– 2200 (0.4)a day 4
2300 (20) –
2600 (20) –
– 3400 (0.6)a day 3
4400 (46) –
– 4500 (0.8)a day 3
– 5600 (1.0)a day 3
6800 (60)a day 5 or 6 –
7800 (60)a day 5 or 6 –
a Animals found dead or euthanized in a moribund condition.
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alterations).
At DM1 doses ≥0.04 mg/kg (~2200 μg DM1/m2) where clinically
signiﬁcant toxicity and morbidity occurred, the histologic ﬁndings
were present in a similar host of tissues (data not shown) but were
signiﬁcantly more severe when compared with the non-tolerated dose
of T-DM1, 60 mg/kg (~6800–7800 μg DM1/m2). Findings included
dose-dependent bone marrow hypoplasia, lymphoid depletion andTable 3
Notable hematologic and clinical chemistry parameters at day 3 from the single-dose T-DM1 a
Parameter, mean (SD) Single-dose T-DM1
Male
Vehicle alone 6 mg/kg
(800 μg
DM1/m2)
20 mg/kg
(2600 μg
DM1/m2)
60
(78
DM
Hematology, thousands/μL
Platelet countsd 1250 (124.4) 1141 (76.1) 711b (314.3) 75
Reticulocyte, absoluted 385.6 (49.16) 310.1b (17.71) 309.8b (40.59) 137
Neutrophil, absoluted 1.40 (0.450) 2.15 (1.421) 5.58b (1.903) 6.6
Lymphocyted 11.19 (4.187) 9.43 (2.064) 8.35 (2.324) 4.6
Clinical chemistry, U/L
ALTd 37 (10.2) 39 (4.7) 115 (42.7) 42
ASTd 189 (39.1) 193 (44.0) 353 (81.8) 94
ALPd 237 (41.8) 226 (53.5) 411a (132.8) 56
GGTc 0 (0.0) 0 (0.0) 1 (2.2)
Total bilirubin 0.1 (0) 0.1 (0) 0.1 (0) 0
Parameter, mean (SD) Single-dose DM1
Male
Vehicle alone 0.05 mg/kg 0.1 mg/kg 0.2
Hematology, thousands/μL
Platelet countsd 1175 (69.1) 926b (132.5) 981a (90.2) 88
Reticulocyte, absoluted 335.2 (63.28) 45.4b (8.91) 42.8b (12.61) 31
Neutrophil, absoluted 0.76 (0.188) 0.45 (0.096) 1.19 (0.470) 2.0
Lymphocytec 6.30 (1.825) 4.64a (0.899) 4.32a (0.662) 3.8
Clinical chemistry, U/L
ALTd 33 (0.8) 35 (2.8) 65b (16.8) 9
ASTd 139 (21.8) 154 (20.4) 246b (39.5) 33
ALPd 259 (77.7) 204 (22.9) 231 (22.9) 17
GGT 1 (0.4) 2 (0.8)a 1 (0.8)
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase
emtansine.
a p b 0.05 compared with control.
b p b 0.01 compared with control.
c p b 0.05 combined treated compared with combined control.
d p b 0.01 combined treated compared with combined control.lymphocytolysis, and cellular necrosis in multiple tissues (hepatocytes
and Kupffer cells in the liver, renal tubular epithelium and urothelium,
skeletal muscle and cardiac myoﬁber, thyroid follicular epithelium,
pancreatic endocrine and exocrine ductular epithelium, and small and
large intestine mucosal epithelium).
Although themajority of ﬁndings were similar for rats administered
T-DM1orDM1, therewere subtle differences in toxicity (e.g., severity or
nature/type of ﬁndings) that are likely related to differences in pharma-
cokinetics, drug distribution, and/or cellular uptake between the mole-
cules. Testicular degeneration, necrosis, and hemorrhage of corpora
lutea, and necrosis of mammary glands were seen in rats given the
highest doses of T-DM1 (60 mg/kg; ~6800–7800 μg DM1/m2), but
they were not observed after any dose of DM1, presumably since rats
could not tolerate DM1 doses greater than 1400–1600 μg DM1/m2
(see Fig. 2A). The administration of DM1 did not result in the
same widespread tissue distribution of cells in mitotic arrest (the
expected pharmacologic action of maytansinoids as microtubule in-
hibitors) that was observed for T-DM1 (Tables 4 and 5), and these
cells were only found in the liver and kidney. At tolerated doses of
T-DM1 (≤20 mg/kg; 2300–2600 μg DM1/m2) or DM1 (≤0.2 mg/kg;
1400–1600 μg DM1/m2), all ﬁndings were partially or completely re-
versed after a 3- or 4-week recovery period, which demonstrates that
the toxic effects of T-DM1 are reversible after a sufﬁcient interval of
time (data not shown).
T-DM1 and DM1 exposures were conﬁrmed in the single-dose rat
studies of T-DM1 (Table A.1) and DM1 (Table A.2). Because T-DM1
has the molecular characteristics of both large-molecule biologic agent
and small-molecule drug, we considered it important to characterize
the TKs by measuring three different analytes: (1) T-DM1 conjugatend DM1 studies in Sprague–Dawley rats.
Female
mg/kg
00 μg
1/m2)
Vehicle alone 6 mg/kg
(700 μg
DM1/m2)
20 mg/kg
(2300 μg
DM1/m2)
60 mg/kg
(6800 μg
DM1/m2)
9b (123.3) 1226 (222.7) 1273 (125.8) 944a (102.6) 769b (144.4)
.4b (15.49) 298.0 (42.99) 285.8 (53.64) 275.7 (30.18) 129.6b (28.65)
8b (1.159) 1.26 (0.280) 0.92 (0.349) 3.67a (1.130) 7.43b (2.179)
1b (1.049) 9.97 (1.274) 7.51a (0.618) 8.40 (1.860) 4.38b (1.090)
4b (165.3) 30 (4.3) 28 (3.7) 62 (9.1) 299b (165.9)
7b (244.9) 217 (61.2) 199 (61.2) 259 (33.0) 789b (375.6)
6b (99.1) 161 (43.3) 149 (49.4) 221 (60.2) 342b (68.4)
1 (1.7) 0 (0.0) 0 (0.0) 0 (0.0) 2 (2.0)a
.3a (0.05) 0.1 (0) 0.2 (0.04) 0.2 (0.04) 0.9a (0.68)
Female
mg/kg Vehicle alone 0.05 mg/kg 0.1 mg/kg 0.2 mg/kg
4b (193.4) 1257 (163.4) 964a (144.8) 1083 (177.9) 792b (186.7)
.7b (6.81) 262.7 (42.03) 51.1b (26.90) 48.9b (14.63) 33.7b (4.68)
2b (0.484) 0.65 (0.122) 0.48 (0.243) 1.09 (0.766) 1.29 (0.598)
4b (0.742) 5.33 (1.405) 6.57 (2.244) 3.91 (0.448) 4.02 (2.052)
1b (17.0) 31 (2.6) 37 (8.3) 55 (38.8) 72b (13.3)
1b (47.0) 125 (29.3) 148 (29.5) 170 (47.3) 316b (44.3)
2b (28.6) 168 (43.4) 150 (33.5) 192 (29.6) 146 (12.6)
1 (0.4) 2 (0.5) 2 (0.9) 2 (.07) 2 (0.0)
; GGT, gamma-glutamyl transpeptidase; SD, standard deviation; T-DM1, trastuzumab
Table 4
Notable microscopic ﬁndings following single-dose administration of 6, 20, and 60 mg/kg T-DM1 in Sprague–Dawley rats at necropsy on days 3, 5, or 6.a
Microscopic ﬁndings Organ/tissue Necropsy results
Day 3b
N (dose, mg/kgc)
Day 5 or 6d
N (dose, mg/kgc)
Degeneration and/or necrosis Liver (hepatocytes, periportal/midzonal) 10 (20), 10 (60) 10 (60)
Spleen (lymphocytes) 4 (60) 3 (60)
Thymus (lymphocytes) 1 (20), 6 (60) 4 (60)
Kidney (tubule) 5 (20), 6 (60) 10 (60)
Duodenum (crypt epithelium) 8 (60)
Testis (seminiferous tubules) 5 (60)e 5 (60)e
Female mammary 3 (60)f 4 (60)g
Male mammary 3 (20), 5 (60)h 3 (60)i
Mesenteric lymph node (lymphocytes) – 2 (60)
Ovary (corpus luteum) – 2 (60)f
Increased mitotic ﬁgures/arrested metaphase Adrenal cortex (diffuse) 4 (60) 10 (60)
Adrenal medulla (diffuse) 2 (60) 3 (60)
Pituitary (pars distalis) 1 (20), 8 (60) 1 (60)
Thyroid (follicular epithelium) 5 (60) 1 (60)
Heart (subepicardial connective tissue) 3 (60)
Tongue (epithelium) 3 (60) 1 (60)
Liver (biliary epithelium) 8 (20), 10 (60) 10 (60)
Liver (hepatocytes) 3 (6), 10 (20), 10 (60) 10 (60)
Liver (Kupffer cells) 7 (6), 10 (20), 10 (60) 10 (60)
Kidney (tubule) 2 (6), 8 (20), 10 (60) 10 (60)
Eye (choroid) 2 (60)
Eye (corneal epithelium) 8 (60) 9 (60)
Skin (epidermis) 5 (60) 5 (60)j
Injection site (epidermis/epidermis adnexa) 4 (60) 5 (60)
Hypertrophy/vacuolation Liver (Kupffer cells) 4 (6), 10 (20), 10 (60) 10 (60)
Spleen (reticuloendothelial cells; with increased mitoses) 4 (20), 10 (60) 10 (60)
Hypocellular Femur marrow 3 (20), 10 (60) 10 (60)
Sternum marrow 10 (60) 10 (60)
Lymphoid depletion Spleen 8 (20), 9 (60) 9 (60)
Thymus – 7 (60)
Mesenteric lymph node – 7 (60)
Other
Luminal debris Epididymis (cellular) 5 (60)e 5 (60)e
Hyperkeratosis Nonglandular stomach – 4 (60)
Hemorrhage Testis – 3 (60)e
T-DM1, trastuzumab emtansine.
a No gross or microscopic observations at recovery necropsy (day 22).
b Data from males and females combined, unless otherwise noted; n = 10 for each dose evaluated.
c 6, 20, and 60 mg/kg T-DM1 doses are equivalent to ~700–800, ~2300–2600, and ~6800–7800 μg DM1/m2, respectively.
d Data frommales and females combined, unless otherwise noted; n = 10 evaluated at T-DM1 60 mg/kg.
e Data from males only; n = 5 for each dose evaluated.
f Data from females only; n = 5 for each dose evaluated.
g Data from females only; n = 4 evaluated at T-DM1 60 mg/kg.
h Data from males only; n = 3 evaluated at T-DM1 20 mg/kg; n = 5 evaluated at T-DM1 60 mg/kg.
i Data from males only; n = 3 evaluated at T-DM1 60 mg/kg.
j Data from ﬁve males and four females, each evaluated at T-DM1 at 60 mg/kg.
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T-DM1, as well as partially unconjugated and fully unconjugated
T-DM1), both measured in rat serum by ELISA, and (3) free DM1mea-
sured in plasma by LC–MS/MS. An integrated analysis revealed that the
TK proﬁle of T-DM1 in rats is consistent with other therapeutic antibod-
ies, as characterized by a terminal t1/2 of approximately 3 to 5 days, a
slow CL ranging from 13 to 15 mL/day/kg, and a central compart-
ment volume approximating the plasma volume. Total trastuzumab
exhibited approximately two-fold slower CL than T-DM1 at all doses
(data not shown). This phenomenon is also observed in monkeys
(Fig. 3) and patients (Girish et al., 2012) and is hypothesized to be
due to deconjugation to lower DAR species, faster clearance of high
DAR species, or a combination of these processes. Free DM1 concentra-
tions (resulting from degradation and release from T-DM1) were at
their peak (8–154 ng/mL) immediately after administration of T-DM1
and decreased in a manner similar to that for T-DM1. In contrast
to the pharmacokinetics of DM1 when conjugated to trastuzumab,
unconjugated DM1 exhibited a large apparent volume of distribution
(N5000 mL/kg) and rapid CL, which is consistent with the pharmacoki-
netic proﬁle expected for a small-molecule compound.Effect of T-DM1 in cynomolgus monkeys
T-DM1 was well tolerated in cynomolgus monkeys with either
single or repeat (q3w × four doses) IV doses up to 30 mg/kg
(~6000 μg DM1/m2) or after chronic administration (q3w × eight
doses) up to the highest dose tested, 10 mg/kg (~2000 μg DM1/m2).
The majority of adverse ﬁndings in cynomolgus monkeys given
T-DM1 were concordant with T-DM1-related toxicity in rats, including
hepatic, bone marrow/hematologic (primarily platelet), lymphoid
organ toxicities, and increased numbers of cells of epithelial and
phagocytic origin in metaphase arrest. Hematologic and lymphoid
organ toxicity was composed of decreased platelet counts, decreased
red cell mass (i.e., erythrocytes, hemoglobin, and hematocrit) with
increased reticulocytes (a rebound response), and lymphoid depletion
in the spleen and thymus (Tables 6, 7, Fig. 4A). Findings pertinent to
the liver included transient elevations of AST, ALT (see Table 6;
Figs. 4B and C), and ALP, and, microscopically, centrilobular vacuolation,
hypertrophy and/or hyperplasia of Kupffer cells, increased sinusoidal
leukocytes, multinucleated hepatocytes, and increased numbers of
Kupffer cells arrested in mitosis (see Table 7). Similar to rats, monkeys
Table 5
Notable microscopic ﬁndings following single-dose administration of 0.07, 0.1, and
0.2 mg/kg DM1 in Sprague–Dawley rats at necropsy on day 3.a
Microscopic ﬁnding Organ/tissue Necropsy results
Nb (dose, mg/kg)c
Degeneration and/or
necrosis
Liver (hepatocytes, periportal/
midzonal)
2 (0.07), 9 (0.1), 10 (0.2)
Liver (biliary epithelium) 3 (0.1), 9 (0.2)
Kidney (tubule) 6 (0.07), 10 (0.1), 9 (0.2)
Thymus (lymphocytes) 3 (0.1), 9 (0.2)
Duodenum (lamina propria) 1 (0.1), 3 (0.2)
Jejunum (lamina propria) 1 (0.2)
Rectum (epithelium) 1 (0.1), 6 (0.2)
Increased mitotic
ﬁgures/arrested
metaphase
Liver (biliary epithelium) 10 (0.07), 10 (0.1), 10 (0.2)
Liver (hepatocytes) 9 (0.07), 10 (0.1), 10 (0.2)
Liver (Kupffer cells) 6 (0.1), 10 (0.2)
Kidney (tubule) 10 (0.07), 10 (0.1), 10 (0.2)
Hemorrhage Femur marrow 8 (0.07), 10 (0.1), 10 (0.2)
Sternummarrow 8 (0.07), 10 (0.1), 10 (0.2)
Hypertrophy/
vacuolation
Liver (Kupffer cells) 2 (0.07), 3 (0.1), 7 (0.2)
Spleen (reticuloendothelial
cells; with increased mitoses)
8 (0.2)
Hypocellular Femur marrow 6 (0.07), 10 (0.1), 10 (0.2)
Sternummarrow 8 (0.07), 10 (0.1), 10 (0.2)
Other
Lymphoid depletion Spleen 5 (0.2)
a Increased mitosis in adrenal cortex of two out of ﬁve females given 0.2 mg/kg seen at
recovery necropsy (day 22); no other gross or microscopic observations at recovery.
b Data from males and females combined, unless otherwise noted; n = 10 for each
dose evaluated.
c 0.7, 0.1, and 0.2 mg/kg DM1 doses are equivalent to ~500, ~700–800, and
~1400–1600 μg DM1/m2, respectively.
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phase mitosis that extended to tissues beyond the liver, indicating
that antigen-dependent or -independent uptake of T-DM1 occurred
with subsequent DM1-driven disruption of cellular division. Tissue
cross-reactivity results from human and cynomolgus monkey frozen
tissue sections showed that membranous staining consistent with10000
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Fig. 3. Toxicokinetic analyses during repeat-dose administration of T-DM1 in female
cynomolgus monkeys. Mean (±SD) concentrations of total trastuzumab, T-DM1, and
DM1 following repeat-dose administration (days 1, 22, 43, and 64) of T-DM1 30 mg/kg
(6000 μg DM1/m2). DM1 concentrations were at least 50-fold lower (on a molar basis)
than T-DM1 at all times (e.g., T-DM1 Cmax = 5.2 μM versus DM1 Cmax = 0.09 μM). SD,
standard deviation; T-DM1, trastuzumab emtansine; Tmab, trastuzumab monoclonal
antibody.tissue binding was detected primarily in epithelial cells of multiple
tissue types (data not shown), consistent with the known expression
of HER2 on normal epithelium (Press et al., 1990), providing support
that mitotic arrest in those tissues is due to antigen-dependent binding
of T-DM1. However, cellular mitotic arrest was even more widespread
in rats, affecting tissues beyond those identiﬁed in the monkey.
This indicates that antigen-independent uptake of T-DM1 can occur
either by Fc-mediated or nonspeciﬁc endocytotic mechanisms, or
through T-DM1 catabolism and subsequent uptake of DM1-containing
catabolites.
A notable adverse ﬁnding observed only in monkeys was microsco-
pic axonal degeneration in the sciatic nerve and dorsal funiculus of the
spinal cord after four doses of 10 or 30 mg/kg (see Table 7, Fig. 5) or
eight doses of 1, 3, or 10 mg/kg (data not shown) that were not revers-
ible within the 6-week recovery period. These observations were
supported by tissue cross-reactivity data from cynomolgus monkey
and human frozen tissue sections in which low-intensity membranous
staining was detected in glial cells and peripheral nerve spindle cells
(presumptive Schwann cells). However, these microscopic changes
did not translate to effects noted during neurologic examinations or
other in-life observations. Nonetheless, the high incidence (14 of 14
animals) and severity (mild to severe) of this neurologic ﬁnding at the
dose of 30 mg/kg was the basis for the calculation of the starting dose
for the phase I clinical study.
The TK analyses of the repeat-dose study (q3w × four doses) in
cynomolgus monkeys conﬁrmed exposure to T-DM1 at 3, 10, and
30 mg/kg (see Fig. 3; Table 8), and dose-proportional TK in the two
higher-dose groups (10 and 30 mg/kg). CL of T-DM1 was faster than
CL of total trastuzumab. Animals treated with 3 mg/kg demonstrated
nonlinear TK with ~50% faster CL of T-DM1 (see Table 8) and total
trastuzumab (data not shown) compared with that in animals treated
with 10 or 30 mg/kg. This observation is consistent with target-
mediated disposition. CL of T-DM1 (see Table 8), total trastuzumab
(data not shown), and DM1 (data not shown) was similar between
sexes at all dose levels. Little or no accumulation of T-DM1was observed
in any dose group (data from female animals treated with T-DM1
30 mg/kg are presented in Fig. 3). Following the administration of
T-DM1, DM1 concentrations were shown to be at least 50-fold lower
(on a molar basis) than T-DM1 at all times (e.g., T-DM1 Cmax = 5.2μM
versus DM1Cmax = 0.09 μM) (see Fig. 3). Exposure to DM1 (maximum
concentration, area under the time–concentration curve for all values
[AUCALL], and/or partial AUC) was proportional to the T-DM1 dose
administered (see Table 7; data not shown). As was observed in rats,
CL of T-DM1 conjugate was faster than CL of total trastuzumab. This
phenomenon is also observed in patients (Girish et al., 2012). DM1
exposures were two-fold higher in rats than in monkeys when given
T-DM1 containing molar equivalent doses of DM1, which may explain,
at least in part, the tolerability differences seen between rats and mon-
keys. The TK proﬁle in cynomolgus monkeys after chronic administra-
tion of T-DM1 (q3w × eight doses) was comparable to the proﬁle in
monkeys administered four doses of T-DM1 (data not shown). The
chronic toxicology study was the only study in which serum ATAs
were detected, and the ﬁnding was limited to four of 36 monkeys
(11%) (n = 3 at 1 mg/kg, n = 1 at 10 mg/kg) (Carrasco-Triguero
et al., 2013). There was no apparent effect of ATAs on TK. Although
animal models are not always predictive of immunogenicity in humans
(Swanson andBussiere, 2012), to date, immunogenicity rates have been
low in T-DM1 clinical trials (Girish et al., 2012).
Cardiovascular safety
When telemeterizedmonkeys were administered a single IV dose of
0, 3, 10, or 30 mg/kg T-DM1, ECG examinations revealed no drug-
related effects on RR or QTc (see Fig. 6A). One individual animal in the
30 mg/kg group had a notably prolonged QTc that was ﬁrst noted on
day 4 and persisted through day 22. The relationship of this ﬁnding to
Table 6
Selected hematologic and clinical chemistry parameters at day 3 from the repeat-dose administration of T-DM1 studies in cynomolgus monkeys.
Parameter, mean (SD) Repeat-dose T-DM1
Male Female
Vehicle
alone
3 mg/kg
(600 μg DM1/m2)
10 mg/kg
(2000 μg DM1/m2)
30 mg/kg
(6000 μg DM1/m2)
Vehicle
alone
3 mg/kg
(600 μg DM1/m2)
10 mg/kg
(2000 μg DM1/m2)
30 mg/kg
(6000 μg DM1/m2)
Hematology, thousands/μL
Platelet counts 434
(119.1)
395
(96.5)
361
(86.7)
380a
(95.0)
418
(128.7)
460
(79.5)
359
(65.1)
452
(151.9)
Reticulocyte, absolute 75.4
(31.34)
78.8
(14.43)
114.5
(27.76)
56.2
(26.92)
73.0
(34.10)
71.0
(18.64)
70.8
(15.75)
60.7
(18.78)
Neutrophil, absolute 4.05
(1.647)
5.62
(2.526)
6.87a
(1.687)
7.47a
(2.363)
3.72
(1.370)
6.69
(2.631)
7.28a
(1.775)
8.53a
(2.909)
Lymphocyte 4.64
(1.429)
4.69
(1.657)
6.38
(2.625)
5.26
(2.479)
6.99
(1.776)
4.54
(1.105)
4.12
(1.339)
4.40a
(1.352)
Clinical chemistry
ALT, U/L 47
(15.2)
69
(21.0)
64
(22.1)
82
(27.0)
45
(16.7)
84
(17.1)
96
(52.2)
169a
(157.5)
AST, U/L 43
(12.7)
70
(15.0)
78a
(20.7)
153a
(37.5)
41
(6.9)
72
(25.1)
98
(34.3)
199a
(101.6)
ALP U/L 459
(113.5)
552
(124.4)
605
(168.1)
951
(508.5)
285
(95.0)
246
(70.9)
307
(125.8)
642a
(232.1)
GGT, U/L 64
(19.5)
81
(29.6)
59
(9.8)
69
(9.3)
52
(14.5)
64
(13.4)
48
(13.8)
65
(12.2)
Total bilirubin, mg/dL 0.3
(0.14)
0.5
(0.63)
0.3
(0.11)
0.3
(0.08)
0.3
(0.04)
0.4
(0.13)
0.3
(0.07)
0.3
(0.14)
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transpeptidase; SD, standard deviation; T-DM1, trastuzumab
emtansine.
a p ≤ 0.05 compared with control.
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imal (decreased body weight, elevated clinical pathology parameters,
including white blood cells, lymphocytes, AST, ALT, and total bilirubin)
that arose during acclimation (posttelemetry implant) and persisted
through the end of the study, combined with a lack of similar changes
in the other animals given 30 mg/kg T-DM1 (including data from the
safety pharmacology study and external ECG data from the repeat-Table 7
Notable microscopic ﬁndings following repeat-dose administration of 3, 10, and 30 mg/kg T-D
Microscopic ﬁnding Organ/tissue
Axonal degeneration Spinal cord (dorsal funiculus)
Sciatic nerve
Hypertrophy and/or hyperplasia Sciatic nerve (Schwann cells)
Liver (Kupffer cells)
Spleen (reticuloendothelial cells)
Increased mitotic ﬁgures/arrested metaphase Liver (Kupffer cells)
Spleen (reticuloendothelial cells)
Tongue (basal epithelium)
Kidneys (tubular epithelial cells)
Mandibular salivary gland (acinar ce
Skin (basal epithelium)
IV site, right saphenous (basal epithe
Lymphoid depletion Spleen (follicular center)
Thymus (grades 1 to 4)
Mesenteric lymph node
Other
Increased sinusoidal leukocytes Liver
Multinucleated hepatocytes Liver
Vacuolation, centrilobular Liver
Increased cellularity, red pulp Spleen
Decreased cytoplasmic granules Mandibular salivary gland
IV, intravenous; T-DM1, trastuzumab emtansine.
a Data frommales and females combined; n = 6 (day 66), 4 (day 85), and 4 (day 106) for e
b T-DM1 doses of 3, 10, and 30 mg/kg are equivalent to ~600, ~2000, and ~6000 μg DM1/mdose toxicity studies — data not shown) suggest that the effects on QT
interval were confounded by factors not related to T-DM1. However
in this same study, potential T-DM1-related effects on hemodynamic
parameters were identiﬁed. These effects were limited to the high-
dose group of 30 mg/kg (about seven times the clinical exposure ob-
served in patients following 3.6 mg/kg T-DM1 administration based
on AUC) (Girish et al., 2012) and consisted of modest increases inM1 in cynomolgus monkeys at necropsy on days 66, 85, and 106.
Day 66 Na
(dose, mg/kg)b
Necropsy results
Day 85 Na
(dose, mg/kg)b
Day 106 Na
(dose mg/kg)b
3 (10), 6 (30) 3 (10), 4 (30) 2 (10), 4 (30)
3 (10), 6 (30) 1 (10), 4 (30) 2 (10), 4 (30)
6 (30) 4 (30) 4 (30)
4 (3), 6 (10), 6 (30) 2 (30)
1 (3), 2 (10), 6 (30)
4 (3), 6 (10), 6 (30) 2 (30) 3 (30)
1 (3), 4 (10), 6 (30) 1 (10), 4 (30)
6 (3), 6 (10), 6 (30)
6 (30)
lls) 1 (30)
6 (3), 6 (10), 6 (30)
lium) 6 (3), 6 (10), 6 (30)
3 (30)
1 (0), 3 (3), 5 (10), 6
(30)
3 (0), 3 (3),
3 (10), 4 (30)
1 (3), 2 (30)
4 (10), 5 (30) 2 (30)
1 (10), 5 (30) 1 (30)
1 (3), 2 (10), 3 (30)
1 (3), 1 (10), 3 (30)
2 (30)
ach dose evaluated.
2, respectively.
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Fig. 4. Percent change from baseline in platelet counts and mean ALT and AST levels over
time from the repeat-dose monkey study (dosed on days 1, 22, 43, and 64 at 0, 3, 10, and
30 mg/kg T-DM1 (~600, ~2000, and ~6000 μg DM1/m2, respectively); male and female
data combined). (A) Platelet counts were decreased 2 days postdose during each dose
cycle for animals administered 30 mg/kg T-DM1, with partial or complete reversibility
at the end of each dose cycle. p ≤ 0.05 decreases/increases relative to control for males
on days 3, 22, and 24, and for females on days 45, 64, and 66. (B) Mean (SD) ALT levels
were elevated 2 days postdose during each dose cycle for animals administered 10 or
30 mg/kg T-DM1, with partial or complete reversibility at the end of each dose cycle.
p ≤ 0.05 increases relative to control at 30 mg/kg for females only on days 3, 22, 24, 43,
45, and 66 and (C) mean AST (SD) levels were elevated 2 days postdose during each
dose cycle for animals administered 10 or 30 mg/kg T-DM1, with partial or complete
reversibility at the end of each dose cycle.) p ≤ 0.05 increases relative to control at
30 mg/kg for males and females on days 3, 24, 43, 45, 64, 66 and 85. Similar cyclic eleva-
tions in alkaline phosphatase were also observed at 30 mg/kg T-DM1 (data not shown).
ALT, alanine aminotransferase; AST, aspartate aminotransferase; SD, standard deviation;
T-DM1, trastuzumab emtansine.
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sures (data not shown) that were variable in onset, magnitude, and
duration in individual monkeys. Peak changes in BP were most consis-
tently observed on day 5 with a trend in reversal by day 22 for three
of four animals. Elevations persisted through day 22 for one animal.
The toxicologic impact of these hemodynamic changes is unclear. Tissue
changes (e.g., tissue congestion or vascular or glomerular changes) that
might reﬂect sustained hypertensive effects were not identiﬁed at nec-
ropsy or in themicroscopic examination of tissues from themonkeys in
the repeat-dose studies.The potential of T-DM1 to induce QT prolongation was investigated
by evaluating the in vitro effects of DM1 on the hERG channel current, a
surrogate for IKr, the rapidly activating, delayed rectiﬁer cardiac potas-
sium current (data not shown). Blockage of this channel is associated
with QT prolongation and torsades de pointes (Raschi et al., 2009).
When DM1 concentrations of 2.6, 8.8, and 29.5 μM (~1.9, ~6.5, and
~21.8 ng/mL) were tested, the inhibitory concentration at 20% (IC20)
and IC50 for the inhibitory effect of DM1 on hERG potassium current
could not be determined and was estimated to be N29.5 μM. Based on
an IC50 of ≥29.5 μM, average plasma DM1 concentrations detected in
T-DM1-treated patients (6 ng/mL), and 93% plasma protein binding, a
safety margin of at least 30-fold was calculated, which is considered
adequate for even nononcology therapeutics (Redfern et al., 2003).
Discussion
T-DM1 was approved by the US Food and Drug Administration in
February 2013 for the treatment of patients with HER2-positive meta-
static breast cancerwhohave received prior treatmentwith trastuzumab
and a taxane, either separately or in combination (Kadcyla package
insert, 2013). Preclinical characterization of toxicities associated with
T-DM1 and DM1 provided early insights into a safety proﬁle that has
been consistent with the most common adverse events in patients to
date (Burris et al., 2011; Kadcyla package insert, 2013; Verma et al.,
2012). Furthermore, the toxicity studies in rats comparing T-DM1 with
DM1 further support the theory that ADCs have the potential to widen
the therapeutic window of potent chemotherapeutic agents.
The mechanism of toxicity of T-DM1 is consistent with the pharma-
cology of DM1 as an inhibitor of tubulin polymerization (Lopus et al.,
2010; Oroudjev et al., 2010). The concordance of toxicities observed in
rats (antigen-nonbinding species) and cynomolgus monkeys (antigen-
binding species) treated with either T-DM1 or DM1 indicates that the
toxicities are primarily antigen-independent and consistent with the
mechanism of action and pharmacologic activity of DM1. In both
species, the hallmark DM1 signature, cellular mitotic arrest, is seen
histologically in the affected target organs. This DM1-drivenmechanism
of toxicity for T-DM1 is supported by a similar nonclinical toxicity pro-
ﬁle for cantuzumab mertansine (C242-DM1), another ADC containing
DM1 as its cytotoxic component (Tolcher et al., 2003). Cantuzumab
mertansine was tolerated by monkeys at doses comparable with
T-DM1 and resulted in increased liver enzymes, axonal degeneration,
and hematopoietic effects. In contrast, trastuzumab has been extremely
well tolerated in extensive nonhuman primate safety evaluations and
lacks any of the ﬁndings associated with T-DM1 administration. Taken
together, these data illustrate that the toxicities observed with T-DM1
are related to DM1, rather than the antibody or chemical linker, and
appear to be generally independent of the target antigen.
T-DM1-related trends in transient cyclic elevations in liver enzymes
and anemia have been consistent between nonclinical species (espe-
cially monkeys) and patients to date. However, theminimal tomild de-
crease in platelet counts observed in the nonclinical species manifested
as the dose-limiting toxicity in patients in the phase I clinical trial at
4.8 mg/kg (Krop et al., 2010). The reason for this difference in sensitiv-
ity between nonclinical species and patients remains unclear, but
in vitro investigations have contributed to a better understanding of
the mechanism of thrombocytopenia (Mahapatra et al., 2011). Experi-
ments of platelet function using platelet-rich plasma or washed plate-
lets have shown that T-DM1 does not have a direct effect on platelet
function (Mahapatra et al., 2011). However, platelet formation experi-
ments using human hematopoietic stem cells (CD133+/CD34+) have
shown that both T-DM1 and an irrelevant binding control ADC (MAb-
DM1) can impair megakaryocyte maturation and subsequent platelet
release. The similarity of effects for both T-DM1 and the MAb-DM1
ADC supports the hypothesis that the observed thrombocytopenia is
an antigen-independent toxicity resulting from exposure to DM1
(Mahapatra et al., 2011). Althoughunconjugated DM1was not included
Control, day 66
10 mg/kg × 4, day 66
30 mg/kg × 4, day 66
10 mg/kg × 4 + 3-week recovery
A B
C D
Fig. 5. Axonal degeneration of sciatic nerves following repeat-dose administration of T-DM1 in cynomolgusmonkeys. At day 66 (2 days after ﬁnal dose), comparedwith (A) control, slight
to severe axonal degeneration was observed following (B) repeat-dose treatment with 30 mg/kg T-DM1 (6000 μg DM1/m2) and (C) Minimal lesions were noted in animals treated with
10 mg/kg (2000 μg DM1/m2). (D) Axonal degeneration was not reversible following a 3-week (day 85) or 6-week (day 106) recovery period (day 106, not shown). T-DM1, trastuzumab
emtansine.
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were observed in rats administered either T-DM1 or DM1, indicating
that this phenomenon can occur whether DM1 is in conjugated or
unconjugated form. In another experiment, megakaryocytes were incu-
bated with Alexa488-conjugated trastuzumab or T-DM1, and surface
binding and internalization were conﬁrmed by immunoﬂuorescence
and ﬂow cytometry. Preincubation with anti-CD32, which binds
and blocks FcRγIIb, decreased Alexa488-conjugated trastuzumab
and T-DM1 antibody binding and uptake by approximately two-
fold, suggesting that FcRγIIb may also partially contribute to the inter-
nalization process and could contribute to the enhanced sensitivity in
patients (Mahapatra et al., 2011).Table 8
T-DM1 TK parameters and DM1 plasma Cmax following repeat-dose administration of T-DM1 (
TK parameter (mean ± SD) T-DM1 dose
3 mg/kg 1
Males Females M
AUC0–inf (day · μg/mL) 189 ± 26.5 195 ± 19.8 8
Cmax (μg/mL) 75.7 ± 6.51 78.0 ± 3.16 2
CL (mL/day/kg) 16.1 ± 2.25 15.3 ± 1.5 1
t1/2 effective (days) 2.43 ± 0.23 2.66 ± 0.12 3
Vss (mL/kg) 56.5 ± 10.0 58.4 ± 3.7 6
DM1 Cmax, ng/mL (mean ± SD) T-DM1 dose
3 mg/kg 1
Males Females M
Dose 1 5.95 ± 0.770 5.85 ± 1.13 2
Dose 2 6.98 ± 1.03 6.72 ± 1.23 2
Dose 3 8.04 ± 0.574 7.09 ± 1.01 2
Dose 4 7.02 ± 0.957 7.53 ± 1.46 2
AUC0–inf, area under the concentration versus time curve from time 0 to inﬁnity; CL, clearance;
effective, effective half-life; T-DM1, trastuzumab emtansine; TK, toxicokinetic; Vss, volume of distPeripheral sensory and motor neuropathy related to nerve axo-
nal degeneration is a known toxicity of microtubule-inhibiting
chemotherapeutic agents, including taxanes, vinca alkaloids, and
auristatins (Adcetris package insert, 2012; Park et al., 2008). Given
thatmaytansines and DM1 share thismechanismof action, it was antic-
ipated that DM1 and possibly T-DM1would cause some degree of neu-
rologic injury. Monkeys given 10 or 30 mg/kg T-DM1 (one- to 10-fold
above the patient exposure range) exhibited varying degrees of axonal
degeneration. Although this histologic ﬁnding did not translate to ob-
servable neurologic deﬁcits, the high incidence (14 of 14 animals) and
severity (mild to severe) of this ﬁnding in monkeys administered
30 mg/kg T-DM1 was the basis for calculation of the starting dose forq3w × four doses) in cynomolgus monkeys.
0 mg/kg 30 mg/kg
ales Females Males Females
71 ± 107.0 930 ± 125.0 2900 ± 552.0 3150 ± 162.0
66 ± 31.8 265 ± 20.7 787 ± 76.9 776 ± 39.9
1.5 ± 1.3 10.7 ± 1.3 10.5 ± 2.3 9.4 ± 0.6
.76 ± 0.51 4.13 ± 0.29 4.63 ± 0.80 5.16 ± 0.23
1.6 ± 6.6 63.7 ± 9.4 68.1 ± 4.7 70.0 ± 4.7
0 mg/kg 30 mg/kg
ales Females Males Females
1.9 ± 1.90 19.6 ± 1.00 74.6 ± 9.27 58.6 ± 2.12
3.6 ± 10.1 24.2 ± 3.39 81.8 ± 9.82 65.1 ± 10.5
5.1 ± 3.99 23.6 ± 3.88 86.1 ± 11.1 66.1 ± 4.70
3.6 ± 2.15 23.4 ± 1.10 76.8 ± 7.55 59.7 ± 4.77
Cmax, maximum observed concentration; q3w, every 3 weeks; SD, standard deviation; t1/2
ribution at steady state.
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Fig. 6. Individual corrected QT interval (QTc) (A), individual aortic systolic pressure (B), and aortic diastolic pressure (C) for 30 mg/kg T-DM1 group versus vehicle control fromdays 1 to 22
of the single dose cynomolgus monkey cardiovascular safety pharmacology study. Similar changes were observed at 30 mg/kg (6000 μg DM1/m2) for mean arterial pressure and pulse
pressure (data not shown). Plotted time points: (predose (−1 h), 24 h postdose, and days 3, 4, 5, 8, 15, and 22).
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patients with breast cancer who were administered the established
clinical dose of 3.6 mg/kg T-DM1 (Burris et al., 2011; Krop et al.,
2012), but, to date, the incidence and severity (mainly ≤grade 2) has
been low, and the condition has beenwellmanagedwith dose reduction
or dose holiday. The mechanisms of T-DM1-induced neurotoxicity
can likely be attributed to both antigen-dependent and -independent
mechanisms. The neurologic effects induced by repeat doses of
maytansine (hind limb paralysis in mice, decreased motor activity inrats, and impairment of the central andperipheral nervous system in pa-
tients) (Issell and Crooke, 1978; Rebert et al., 1984; Sieber et al., 1978)
suggest that the neurologic toxicity of T-DM1 is antigen-independent
and driven by the DM1 component of the molecule. This theory is also
supported by ﬁndings of neurologic toxicity in cynomolgus monkeys
treated with non-HER2 targeting cantuzumab mertansine (Tolcher
et al., 2003). In studies of T-DM1 and DM1 in rats and T-DM1 in
cynomolgus monkeys, however, the ﬁndings suggest that there may
be an antigen-dependent contribution to the neurologic toxicity as
311K.A. Poon et al. / Toxicology and Applied Pharmacology 273 (2013) 298–313well. Only monkeys (a HER2-binding species) exhibited axonal de-
generation, and the neurologic effects seen with maytansine were not
reproduced in rats given either T-DM1 or DM1. Based on tissue cross-
reactivity experiments, low-level HER2-dependent staining was ob-
served in monkey and human glial cells and peripheral nerve spindle
cells (presumptive Schwann cells), indicating that T-DM1 effects on
the nerve may be partially antigen-dependent andmay, in part, explain
the presence of this ﬁnding in monkeys. The absence of neurologic tox-
icity in ratsmay be explained both by the limited exposure toDM1 from
a single dose of T-DM1 or DM1 and by the lack of antigen-dependent
contributions to this pathology. Based on the neurologic effects induced
inmice and humanswithmaytansine, the axonal degeneration observed
in monkeys given T-DM1 or cantuzumab mertansine (HER2 antigen-
binding and -nonbinding DM1-ADCs, respectively), and low-grade pe-
ripheral neuropathy observed in humans administered T-DM1, it is likely
that a combination of antigen-dependent and -independent mecha-
nisms underlie the neurologic toxicity of T-DM1 observed in these
studies.
Although cardiotoxicity was also not identiﬁed in trastuzumab pre-
clinical studies (Klein and Dybdal, 2003), clinically, trastuzumab has
been associated with an increased risk of cardiac dysfunction, and this
risk is increased when trastuzumab is given in combination with
anthracyclines (De Keulenaer et al., 2010; Seidman et al., 2002). Given
this phenomenon, we hypothesized that the conjugation of a cytotoxic
component to trastuzumab had the potential to enhance this liability.
The results from the cynomolgus monkey cardiovascular safety study
did not reveal any signiﬁcant changes to ECG parameters, including
QTc (see Fig. 6A). Also, therewas no evidence of cardiomyocyte damage
in the ventricle, atrium, or atrial–ventricular valve evaluated histopath-
ologically in the single- or multiple-dose T-DM1 studies in monkeys. In
addition, DM1 did not inhibit the hERG channel current at concentra-
tions up to 30-fold higher than the fraction of unboundDM1 in clinically
relevant doses of trastuzumab. These results are consistent with ﬁnd-
ings froma phase II dedicatedQT study inwhich T-DM1hadminimal ef-
fects on QT prolongation at the proposed therapeutic dose (3.6 mg/kg
T-DM1 q3w) (Gupta et al., 2013). T-DM1-related effects on hemody-
namic parameters were identiﬁed in the monkey safety pharmacolo-
gy study (Figs. 6B and C), but the mechanism of this effect is unclear
and was variable in onset, magnitude, and duration in individual
monkeys. Chronic administration of T-DM1 was not associated
with evidence of hypertension in monkeys, and the incidence of
hypertension in patients has been low and primarily grade 1 or 2 to
date (Kadcyla package insert, 2013). In total, results from the preclinical
toxicity and safety pharmacology studies showed that T-DM1, like
trastuzumab, is not associatedwith acute changes in cardiac conduction
or hemodynamic parameters. However, cardiac dysfunction resulting in
reduced left ventricular ejection fraction that is observed in some
trastuzumab patients and results in drug discontinuation was not
measured in these studies.
DM1 and maytansine are closely related chemical entities of the
same maytansinoid class and are considered equipotent based on data
from acute toxicity studies: The LD10 of maytansine is ~0.4 mg/kg, and
DM1 is not tolerated at ≥0.4 mg/kg (2400 μg DM1/m2) (Issell and
Crooke, 1978; Mugera and Ward, 1977) (see Fig. 2). Maytansine is
embryotoxic, teratogenic, and clastogenic in mice at single intraperito-
neal doses of 0.1 mg/kg, 0.2 mg/kg, and 0.25 mg/kg (Issell and Crooke,
1978; Sieber et al., 1978). Importantly, when rats are administered sim-
ilar doses of DM1 (0.07 mg/kg, 0.1 mg/kg, or 0.2 mg/kg) intravenously,
their plasma DM1 concentrations (5–28 ng/mL) are comparable with
the range of plasma DM1 concentrations achieved in patients given
3.6 mg/kg T-DM1 q3w (Girish et al., 2012). Hence, patients will be
exposed to concentrations of DM1 that have been (indirectly) shown
to lead to fetal harm, irrespective of whether the fetus is exposed to
signiﬁcant levels of T-DM1 during organogenesis.
Another outcomeof the studies reported herewas the demonstrated
improvement in tolerability that resulted from conjugation of DM1 totrastuzumab. The single-dose rat toxicity studies indicate that the
tolerated dose of DM1 when conjugated to trastuzumab is approxi-
mately two-fold greater than the dose-equivalent of unconjugated
DM1 alone. When mortality occurred in rats given DM1 at
2200 μg DM1/m2, T-DM1 was tolerated at equivalent DM1 doses up
to 4400 μg DM1/m2. A similar comparison can be made clinically be-
tween T-DM1 and the parent compound of DM1, maytansine, which
was evaluated in phase I and phase II clinical trials in the late 1970s.
Maytansine proved to have too narrow a therapeutic index, which
resulted in the discontinuation of its development. Although anti-
tumor responses were observed at doses of 1.6 and 2.0 mg/m2 in pa-
tients with solid tumor or hematologic cancers, the beneﬁcial effects
were accompanied by dose-limiting toxicities after a limited number
of treatment cycles, including profound weakness, severe nausea and
vomiting, and neurologic toxicity (Chabner et al., 1978; Chahinian
et al., 1979). Given the chemical similarity and comparable potency of
maytansine and DM1, it is likely that administration of DM1 would re-
sult in a similar clinical proﬁle. By contrast, 3.6 mg/kg T-DM1 (approx-
imately 2.3 mg DM1/m2) has been well tolerated in patients treated
over multiple cycles (Verma et al., 2012). The ﬁndings from the acute
toxicity assessments in rats support the apparent differences in tolera-
bility seen clinically between maytansine and T-DM1.
In summary, T-DM1 had a favorable safety proﬁle in preclinical
studies. The differences in species and patient sensitivity and/or
toxicity proﬁle may be due to differences in exposure to T-DM1
and/or DM1 and the impact of antigen distribution and binding,
but overall the toxicity proﬁle translated well from rat to monkey
to human. The toxicities associated with T-DM1 and DM1 are
well characterized, predictable, and consistent with the mechanism
of action and pharmacologic activity of DM1. Finally, the studies of
T-DM1 and DM1 in rats, and the emerging differences in patient
tolerability for T-DM1 versus maytansine, uphold the premise that
ADCs have the potential to improve the therapeutic window for
cytotoxic agents.
Supplementary data to this article can be found online at http://dx.
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T-DM1 toxicokinetic parameters and DM1 plasma Cmax measurement following single-dose administration of T-DM1 in Sprague–Dawley rats (total trastuzumab data not shown).
TK parameter (mean ± SDa) T-DM1 dose
6 mg/kg 20 mg/kg 60 mg/kgb
Males Females Males Females Males Females
AUC0–inf (day · μg/mL) 426 ± 28.1 436 ± 18.4 1520 1330 – –
AUC0–3 (day · μg/mL) 206 ± 3.34 198 ± 3.09 683 ± 14.0 598 1820 ± 86.8 1500 ± 98.91
CL (mL/day/kg) 13.8 ± 0.896 13.5 ± 0.581 13.1 15.0 – –
Cmax (μg/mL) 162 ± 11.0 168 ± 3.88 489 ± 27.7 432 1720 ± 81.9 1510 ± 223
t1/2 effective (days) 3.80 ± 0.126 4.08 ± 0.196 4.66 4.57 – –
Vss (mL/kg) 56.5 ± 10.0 58.4 ± 3.7 61.6 ± 6.6 63.7 ± 9.4 68.1 ± 4.7 70.0 ± 4.7
T-DM1 dose
6 mg/kg 20 mg/kg 60 mg/kg
Males Females Males Females Males Females
DM1 Cmax, ng/mL 13.2 ± 2.11 8.27 ± 0.858 43.9 ± 1.38 59.6 ± 0.778 124 ± 12.9 154 ± 13.9
AUC0–inf, area under the concentration versus time curve from time 0 to inﬁnity; AUC0–3, area under the concentration versus time curve from 0 to 3 days; Cmax, maximum observed
concentration; CL, clearance; SD, standard deviation; t1/2, effective, effective half-life; T-DM1, trastuzumab emtansine; TK, toxicokinetic; Vss, volume of distribution at steady state.
a SD not available for some parameters/doses because n = 2/sex.
b Only exposure parameters (AUC0–3 and Cmax) are reported at 60 mg/kg because of animal mortality.
Table A.2
DM1 toxicokinetic parameters following single-dose administration of DM1 in Sprague–Dawley rats.
TK parameter (mean ± SD) DM1 dose
0.07 mg/kg 0.1 mg/kg 0.2 mg/kg
Males Females Males Females Males Females
AUC0–inf (min · ng/mL) 1290 ± 140 1530 ± 528 2940 ± 883 3950 ± 664 6340 ± 906 9160 ± 1090
Cmax (ng/mL) 9.67 ± 2.03 8.71 ± 0.0316 13.8 ± 1.36 13.9 ± 1.13 22.5 ± 2.62 28.2 ± 2.89
CL (mL/min/kg) 52.0 ± 6.19 46.7 ± 16.1 39.2 ± 9.38 27.3 ± 4.70 31.6 ± 4.83 21.4 ± 1.80
t1/2 terminal (min) 214 ± 28.4 304 ± 116 377 ± 126 546 ± 105 548 ± 62.8 673 ± 87.1
Vss (mL/kg) 14,300 ± 1340 17,100 ± 1070 18,600 ± 1300 19,900 ± 1450 23,700 ± 4740 19,800 ± 2550
AUC0–inf, areaunder the concentration versus time curve from0 to inﬁnity; CL, clearance; Cmax,maximumobserved concentration; SD, standarddeviation; t1/2 terminal, terminal half-life; TK,
toxicokinetic; Vss, volume of distribution at steady state.References
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